Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib + temozolomide for recurrent glioblastoma
ChiCTR2000028853Phase 4Not yet recruiting
- Sponsor
- Tangdu Hospital
- Start
- Feb 2020
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of anlotinib and temozolomide in glioblastoma (GBM), sponsored by Tangdu Hospital. Primary endpoint: Overall survival. Planned start Feb 2020; status: not yet recruiting.
02
Drugs
anlotinibtemozolomide
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on ChiCTR2000028853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000028853.